Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

This study has been completed.
Sponsor:
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.
ClinicalTrials.gov Identifier:
NCT00334399
First received: May 26, 2006
Last updated: October 8, 2008
Last verified: October 2008
  Purpose

The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: Miglitol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

  Eligibility

Ages Eligible for Study:   20 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetic patients treated with Biguanide
  • Criteria for postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

  • Type 1 diabetes
  • Patients treated with other antidiabetic drugs or Insulin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334399

Locations
Japan
Aichi, Japan
Chiba, Japan
Fukuoka, Japan
Gifu, Japan
Gunma, Japan
Hokkaido, Japan
Ibaragi, Japan
Kanagawa, Japan
Kumamoto, Japan
Miyazaki, Japan
Osaka, Japan
Saitama, Japan
Tochigi, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Investigators
Study Director: Clinical Study Group, Clinical Development Dept. Sanwa Kagaku Kenkyusho Co., Ltd.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00334399     History of Changes
Other Study ID Numbers: MG1008
Study First Received: May 26, 2006
Last Updated: October 8, 2008
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpa-glucosidase inhibitor,Biguanide

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Miglitol
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 25, 2014